February 23, 2024 10:22 AM EST
News Briefing

Karuna push­es back KarXT da­ta read­outs; Vir, GSK end flu col­lab­o­ra­tion; Si­lence’s $10M mile­stone pay­ment

Kyle LaHucik

Senior Reporter

Reynald Castañeda

Deputy Editor

Ayisha Sharma

News Reporter

Plus, news about Co­gent and In­di­v­ior:

Karuna de­lays some KarXT read­outs: As the drug­mak­er awaits clos­ing of its large ex­it to Bris­tol My­ers Squibb and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

Mer­ck fi­nal­ly has sub­cu­ta­neous Keytru­da re­sults, and it's go­ing to reg­u­la­tors

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times